Inspire Medical Systems (INSP)
(Delayed Data from NYSE)
$191.48 USD
+5.13 (2.75%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $191.38 -0.10 (-0.05%) 7:58 PM ET
1-Strong Buy of 5 1
F Value A Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$191.48 USD
+5.13 (2.75%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $191.38 -0.10 (-0.05%) 7:58 PM ET
1-Strong Buy of 5 1
F Value A Growth B Momentum B VGM
Zacks News
Here's Why You Should Retain Henry Schein (HSIC) Stock for Now
by Zacks Equity Research
Favorable Dental business trends and expansion efforts through acquisitions and partnerships bode well for Henry Schein (HSIC).
UnitedHealth Group (UNH) Tops on Q1 Earnings, Reaffirms EPS View
by Zacks Equity Research
UnitedHealth Group (UNH) first-quarter earnings benefit from strong Optum and UnitedHealthcare business lines. Rising expenses partially offset the positives.
Labcorp (LH) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Labcorp (LH) is anticipated to drive growth in the first quarter of 2024 through base business expansion, integrating acquisitions and partnerships and advancing in science and technology.
Will Elevance (ELV) Beat Q1 Earnings on Carelon Strength?
by Zacks Equity Research
The first-quarter results of Elevance (ELV) are likely to reflect higher product revenues and Commercial Individual membership growth.
Quest Diagnostics (DGX) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Acquisitions and partnerships with health plans are expected to drive Quest Diagnostics' (DGX) base business performance in the first quarter of 2024.
Can High Medical Costs Affect UnitedHealth's (UNH) Q1 Earnings?
by Zacks Equity Research
UnitedHealth's (UNH) first-quarter results are likely to reflect growth in premium levels and service revenues.
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Will UnitedHealth's (UNH) UnitedHealthcare Unit Aid Q1 Earnings?
by Zacks Equity Research
UnitedHealth's (UNH) first-quarter results are expected to benefit from an increase in UnitedHealthcare's Community & State revenues and the number of people it served.
New Strong Buy Stocks for April 9th
by Zacks Equity Research
SRDX, X, TELNY, INSP and MTAL have been added to the Zacks Rank #1 (Strong Buy) List on April 9, 2023.
3 Medical Info Systems Stocks to Buy as Industry Improves
by Urmimala Biswas
A few Zacks Medical Info Systems industry stocks like Inspire Medical Systems (INSP), Talkspace (TALK) and Health Catalyst (HCAT) are expected to gain from the new normal trends.
Here's Why You Should Retain Inspire Medical (INSP) Stock Now
by Zacks Equity Research
Inspire Medical's (INSP) focus on R&D raises optimism about the stock.
Brookdale Senior's (BKD) Q4 Loss Widens, Shares Drop 13%
by Zacks Equity Research
Brookdale Senior's (BKD) Q4 results were hit by inflationary challenges, an increase in facility operating lease expense and higher income tax provision. It expects adjusted EBITDA within $90-$95 million in first-quarter 2024.
Encompass Health (EHC) Q4 Earnings Beat on Higher Discharges
by Zacks Equity Research
Encompass Health's (EHC) Q4 results gain on improved net patient revenue per discharge and higher net income. Management estimates 2024 adjusted EPS to be $3.77-$4.06.
Inspire Medical (INSP) Q4 Earnings Top Estimates, Gross Margin Up
by Zacks Equity Research
Inspire Medical's (INSP) U.S. region witnesses strong revenue growth in the fourth quarter.
Compared to Estimates, Inspire (INSP) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Inspire (INSP) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Inspire Medical Systems (INSP) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Inspire (INSP) delivered earnings and revenue surprises of 1,325% and 0.05%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Inspire Medical Systems (INSP) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Inspire (INSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Inspire Medical (INSP) Reports Solid Preliminary Q4 Revenues
by Zacks Equity Research
Inspire Medical's (INSP) revenue growth in the fourth quarter is likely to have been boosted by improved operating leverage.
3 Reasons to Hold Inspire Medical (INSP) Stock in Your Portfolio
by Zacks Equity Research
Inspire Medical's (INSP) focus on R&D raises optimism about the stock.
Inspire (INSP) Up 16.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Inspire (INSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
3 Reasons to Retain Inspire Medical (INSP) Stock for Now
by Zacks Equity Research
Inspire Medical's (INSP) focus on R&D raises optimism about the stock.
Inspire Medical (INSP) Q3 Earnings Top Estimates, Revenues Lag
by Zacks Equity Research
Inspire Medical's (INSP) both geographic regions witness strong revenue growth in the third quarter.
Charles River (CRL) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Charles River's (CRL) CRADLE initiative and research models in North America and China are anticipated to have maintained their growth momentum in the third quarter.
Inspire Medical Systems (INSP) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Inspire (INSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Penumbra (PEN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Penumbra (PEN) will likely report strong Neuro sales growth on the strength of its RED 72 (with the proprietary SENDit technology), RED 43 and BMX81.